RecruitingPhase 2NCT07111546

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 02(BTC&HCC)]

Sponsor

Nanjing Leads Biolabs Co.,Ltd

Enrollment

140 participants

Start Date

Oct 20, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumour

Summary

An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bevacizumab Injection, a drug called Cisplatin Injection, and others for people with advanced solid tumour. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLBL-024 for Injection

Intravenous infusion.

DRUGCisplatin Injection

Intravenous infusion.

DRUGGemcitabine Hydrochloride for Injection

Intravenous infusion.

DRUGBevacizumab Injection

Intravenous infusion.

Locations(8)

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China

Shandong Cancer Hospital

Jinan, Shandong, China

Zhongshan Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Sir Run Run Shaw Hospital (SRRSH) Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07111546

Related Trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

NCT0678364724 locations

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

NCT073311557 locations

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

NCT073903837 locations